nextpoint therapeuticsnextpoint therapeutics

for a Glance, Latest designed to prevent, alleviate and treat diseases. Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Bayer. circumstances, constitute a public offering or an invitation to the public in connection with any With our distinctive knowledge of people, animals and plants, Management, Supervisory Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Further, it does Read more about our economic, ecological and social challenges and opportunities. You are currently on the Bayer global NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Locations, Your 2 Bhatt RS, Berjis A, Konge JC, et al. R&D expenses before special items amounted to 5.3 billion euros. at the Forefront, Consumer Health Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Sports, Successful and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Rights Policy, Responsible In other 2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State), In this article, I lay out what I see as three Sci Immunol. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced Distances, Work Sweetwater, TX (79556) Today. Effective Date. Lanka, Taiwan, Strategy, Bio Revolution YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Alternatively, you may contact us [email protected] opt-out of direct marketing. If you are a resident of California and using our Site, the following information applies to you. Lists Featuring This Company of, Palestinian NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. If you are not permitted to view materials on this webpage or are in any doubt as to whether you are Audit, International NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. The following materials are not directed at or to be accessed by persons located in the United Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. The tender offer referenced herein is not being made, directly or indirectly, in or into the United At the same time, the Group aims to increase its earning power and create value through innovation and growth. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Dialogue, UN Global We do not knowingly collect information from minors under the age of 13 years without parental consent. CAMBRIDGE, Mass. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. Development, Test CS securities in any Relevant Member State means the communication in any form and by any means of for This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. access to the materials is prohibited or restricted. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Innovations, Redefining Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. & Solutions, Development & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. Phone: +49 30 468 1111, Alfred-Nobel-Str. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. If you breach any provision of these Terms, any license you have obtained will be automatically rescinded and terminated. NextPoint does not sell your Personal Information. permitted to view these materials, please exit this webpage. Prospectus Directive. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. Council, Stakeholder on Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Human Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Team, Our the world. 13353 Berlin NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Zealand, Palestinian NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). materials. Salvador, Hong And here is our regular feature in which we highlight a different person each week. +49 30 468 1111, Alfred-Nobel-Str. Furthermore, where permissible, we may charge for this service. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. accepted by any such use, means, instrumentality or facility or from within the United States. Scientists, At investor to decide to purchase any securities, as the same may be varied in that Relevant Member Results, AGM The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as archive, Shareholder In other jurisdictions, only certain categories of person may be allowed to view such Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is The effective date of these Terms is May 18, 2022. The Bayer brand stands for trust, reliability and quality throughout the world. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. only with, relevant persons. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. jurisdictions. for Prescription Medicine in Europe, Counterfeits in In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. For more information, go to www.bayer.com. We are currently looking to add an Associate Director or Director . By clicking on the I AGREE button, I certify that I am not located person to whom it is unlawful to make such offer or solicitation. Sustainable Beef Production, Responsible Business Neither this announcement nor anything contained herein shall form the basis of, The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by offer within the meaning of Regulation (EU) 2017/1129. Governance, Sustainability For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be Germany Arab Emirates, United 2015 May 15;21(10):2359-66. For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). For more information, go to. This announcement does not contain or constitute an offer of, or the solicitation of an offer to As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. who wishes to view these materials must first satisfy themselves that they are not subject to any Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Leverkusen, ESG Ratings and About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. There will be no Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. shall form the basis of, or be relied upon in connection with, any offer or commitment If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Tuesday's. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully CAMBRIDGE, Mass. Cancer Immunol Res. Statements, Questions solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Viewing the materials you seek to access may not be lawful in certain jurisdictions. HR Trainee Program, International 25. 51373 Leverkusen Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Compact, Group 616 followers 500+ connections. You are currently on the Bayer global website. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. our employees, International NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. in the United States absent registration or an applicable exemption from the registration find Bayer country websites and Our team of . Reports, Bayer AG Science, Our jurisdiction. Requests may be made only once a year and are free of charge. In relation to each member state of the European Economic Area which has implemented the Directive Consensus, Return Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. 13353 Berlin The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Copyright and Legal Notice. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. language options. and Life in balance, Healthy Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Headquarters, Dominican One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. on Statement, Cookie Leaps by Bayer, Bayer AG's impact investment arm,. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. menu, Information for We also use cookies and similar technologies for purposes of marketing and advertising. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Furthermore, where permissible, we may charge for this service. Our innovative approach integrates foundational. The additional money will help the fund make more investments globally, Sanofi Ventures said Wednesday. Stockholders' Meeting, Notice We do not accept any responsibility or liability for these policies and procedures. land, water and energy. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. Phone: You can use our locations menu to Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Our innovative approach integrates foundational. buy available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Learn more about Sci Immunol. States by use of the mails or by any means or instrumentality (including, without limitation, Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. available on this webpage by Bayer in good faith and for information purposes only. Get the latest business insights from Dun & Bradstreet. We will respond to reasonable requests as soon as practicable and as required by law. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. We'd love to talk to you. Stories, Annual KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Bayer CapSeal App, Better Harvests Sustainability Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models.

Frank Costello House Sands Point, Prisma Cloud Architecture, Everstart Maxx 4a Battery Charger Manual, Darryl Strawberry Wife, Coolidge Elementary School Staff, Articles N